Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in PTC Therapeutics, Inc. or Immunocore Holdings plc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how PTC Therapeutics, Inc. and Immunocore Holdings plc compare based on key financial metrics to determine which better meets your investment needs.

About PTC Therapeutics, Inc. and Immunocore Holdings plc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich’s ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company’s products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Latest Biotechnology and PTC Therapeutics, Inc., Immunocore Holdings plc Stock News

As of November 25, 2025, PTC Therapeutics, Inc. had a $6.7 billion market capitalization, compared to the Biotechnology median of $209.4 million. PTC Therapeutics, Inc.’s stock is up 91.1% in 2025, up 14.1% in the previous five trading days and up 93.36% in the past year.

Currently, PTC Therapeutics, Inc.’s price-earnings ratio is 9.3. PTC Therapeutics, Inc.’s trailing 12-month revenue is $1.8 billion with a 42.3% net profit margin. Year-over-year quarterly sales growth most recently was 7.2%. Analysts expect adjusted earnings to reach $8.795 per share for the current fiscal year. PTC Therapeutics, Inc. does not currently pay a dividend.

As of November 25, 2025, Immunocore Holdings plc had a $2.0 billion market cap, putting it in the 56th percentile of all stocks. Immunocore Holdings plc’s stock is up 36% in 2025, up 3.8% in the previous five trading days and up 19.34% in the past year.

Currently, Immunocore Holdings plc does not have a price-earnings ratio. Immunocore Holdings plc’s trailing 12-month revenue is $379.6 million with a -7.7% net profit margin. Year-over-year quarterly sales growth most recently was 29.3%. There are no analysts providing consensus earnings estimates for the current fiscal year. Immunocore Holdings plc does not currently pay a dividend.

How We Compare PTC Therapeutics, Inc. and Immunocore Holdings plc Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at PTC Therapeutics, Inc. and Immunocore Holdings plc’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

PTC Therapeutics, Inc. and Immunocore Holdings plc Stock Value Grades

Company	Ticker	Value
PTC Therapeutics, Inc.	PTCT	B
Immunocore Holdings plc	IMCR	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

PTC Therapeutics, Inc. has a Value Score of 72, which is Value. Immunocore Holdings plc has a Value Score of 10, which is Ultra Expensive.

The Value Stock Winner: PTC Therapeutics, Inc.

As you can clearly see from the Value Grade breakdown above, PTC Therapeutics, Inc. is considered to have better value than Immunocore Holdings plc. For investors who focus solely on a company’s valuation, PTC Therapeutics, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

PTC Therapeutics, Inc. and Immunocore Holdings plc’s Quality Grades

Company	Ticker	Quality
PTC Therapeutics, Inc.	PTCT	A
Immunocore Holdings plc	IMCR	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

PTC Therapeutics, Inc. has a Quality Score of 89, which is Very Strong. Immunocore Holdings plc has a Quality Score of 59, which is Average.

The Quality Grade Winner: PTC Therapeutics, Inc.

As you can clearly see from the Quality Grade breakdown above, PTC Therapeutics, Inc. has a better overall quality grade than Immunocore Holdings plc. For investors who are looking for companies with higher quality than others in the same industry, PTC Therapeutics, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

PTC Therapeutics, Inc. and Immunocore Holdings plc’s Momentum Grades

Company	Ticker	Momentum
PTC Therapeutics, Inc.	PTCT	A
Immunocore Holdings plc	IMCR	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

PTC Therapeutics, Inc. has a Momentum Score of 94, which is Very Strong. Immunocore Holdings plc has a Momentum Score of 72, which is Strong.

The Momentum Grade Winner: PTC Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, PTC Therapeutics, Inc. is considered to have stronger momentum compared to Immunocore Holdings plc. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, PTC Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other PTC Therapeutics, Inc. and Immunocore Holdings plc Grades

In addition to Quality, Value and Momentum, A+ Investor also provides grades for Growth and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether PTC Therapeutics, Inc. and Immunocore Holdings plc pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, PTC Therapeutics, Inc. or Immunocore Holdings plc Stock?

Overall, PTC Therapeutics, Inc. stock has a Value Score of 72, Momentum Score of 94 and Quality Score of 89.

Immunocore Holdings plc stock has a Value Score of 10, Momentum Score of 72 and Quality Score of 59.

Comparing PTC Therapeutics, Inc. and Immunocore Holdings plc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.